HUMA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.0M
+153.2%
406.0K
-18.0%
495.0K
+6.0%
467.0K
-38.0%
753.0K
Cost of Revenue
1.4M
+16.1%
1.2M
-39.6%
2.0M
-77.6%
9.1M
+3393.1%
260.0K
Gross Profit
-401000
+51.4%
-825000
+46.5%
-1543000
+82.1%
-8615000
-1847.5%
493.0K
Operating Expenses
19.7M
-31.7%
28.9M
+5.5%
27.4M
+23.3%
22.2M
+11.2%
20.0M
R&D
14.1M
-22.3%
18.1M
-6.8%
19.5M
+33.3%
14.6M
-15.4%
17.3M
SG&A
9.0M
+12.3%
8.0M
+1.2%
7.9M
+4.1%
7.6M
+0.1%
7.6M
Operating Income
-20132000
+32.2%
-29714000
-2.7%
-28935000
+6.2%
-30836000
-58.2%
-19497000
EBITDA
-18855000
+33.6%
-28377000
-2.8%
-27593000
+11.2%
-31065000
-71.1%
-18155000
Net Income
-15538000
+57.8%
-36802000
-108.9%
-17619000
+29.0%
-24804000
-41.7%
-17510000
EPS (Basic)
$-0.06
+62.5%
$-0.16
-77.8%
$-0.09
+30.8%
$-0.13
-18.2%
$-0.11
EPS (Diluted)
$-0.06
+62.5%
$-0.16
-77.8%
$-0.09
+30.8%
$-0.13
-18.2%
$-0.11
Shares (Diluted)
277.8M
+18.6%
234.2M
+18.4%
197.8M
+5.7%
187.1M
+18.2%
158.3M
Humacyte (HUMA) — Financials